- Product Theatres will take place at the Henry B. Gonzalez Convention Center
Advancing the Standards of Breast Cancer Care with Comprehensive Somatic Next-Generation Sequencing, Germline Testing and AI-Driven Data
Presented by Tempus
A First-Line CDK4/6 Inhibitor Combination Therapy: Clinical Trial Evidence Complemented by a Real-World Effectiveness Evaluation
Presented by Pfizer
Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer
Presented by Gilead Sciences, Inc.
MammaPrint & BluePrint: Gene Expression Profiling for Risk of Distant Metastasis in Early-Staged Breast Cancer Tumors and Molecular Subtyping Driving its Growth
Presented by Agendia, Inc.
The Predictive Power of the Breast Cancer Index H/I Biomarker: Extended Endocrine Therapy and Beyond
Presented by Biotheranostics, A Hologic Company
Clinical Trial Data update for a HER2+ MBC treatment option
Presented by Seagen Inc.
Laying the Groundwork: Current and Future Applications of Signatera™ in Breast Cancer
Presented by Natera
Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings
Presented by Lilly Oncology
The Evolving Role of the Oncotype Dx Breast Recurrence Score® Test and the Future of the Breast Cancer Care Continuum
Presented by Exact Sciences
Featured Product Theatre
The Efficacy and Safety of ENHERTU
Presented by Daiichai Sankyo, Inc., and AstraZeneca